SCHEMBL91517

SCHEMBL91517

CN(C)[C@H]1CCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL132685 1.00
SCHEMBL64636 1.00
Hydrochloric Acid SCHEMBL1720052 0.97
Hydrochloric Acid SCHEMBL18424739 0.97 SLC6A4 (0.38)
Hydrochloric Acid SCHEMBL15048805 0.97
Hydrochloric Acid SCHEMBL14719361 0.97 SLC6A4 (0.38)
Hydrochloric Acid SCHEMBL15048768 0.97
Hydrochloric Acid SCHEMBL8178088 0.97 SLC6A4 (0.38)
Formaldehyde SCHEMBL27898967 0.93 SLC6A4 (0.37)
SCHEMBL249249 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3755330-A1 PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF Dana-Farber Cancer Institute, Inc. (US) 2020-12-30 EP claimed
EP-3755338-A1 PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF Dana Farber Cancer Institute, Inc. (US) 2020-12-30 EP claimed
WO-2019164941-A1 PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-08-29 WO claimed
WO-2019164945-A1 PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-08-29 WO claimed
CN-108191861-A N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls]-trans- -2,4- Pentadienamides 天津大学 2018-06-22 CN claimed
EP-3299358-A1 AMIDE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2018-03-28 EP claimed
EP-2058302-B1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE EISAI R&D MAN CO LTD (JP) 2013-04-17 EP claimed
US-7790885-B2 Process for preparing phenoxypyridine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-09-07 US claimed
CN-101454286-A Process for producing phenoxypyridine derivative EISAI R&D MAN CO LTD (JP) 2009-06-10 CN claimed
EP-2058302-A1 METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2009-05-13 EP claimed
US-20080214815-A1 Process for preparing phenoxypyridine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-09-04 US claimed
US-20260115194-A1 NEW TREATMENTS FOR PAIN SEVENLESS THERAPEUTICS LTD (GB) 2026-04-30 US disclosed
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 WO disclosed
EP-4725554-A2 COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES Yuhan Corporation (KR) 2026-04-15 EP disclosed
EP-4711369-A1 1H-[1,2,3]TRIAZOLO[4,5-H]QUINAZOLINE COMPOUNDS AS PROTEIN KINASE INHIBITORS Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. (CN) 2026-03-18 EP disclosed
US-5547962-A QUINOLONE ANTIBIOTICS HORURIKU SEIYAKU CO., LTD. (JP) 1996-08-20 US disclosed
CN-1117491-A 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative NORTHERN CONTINENTAL CO LTD (JP) 1996-02-28 CN disclosed
EP-0641793-A1 5-Amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative HOKURIKU SEIYAKU CO., LTD. (JP) 1995-03-08 EP disclosed
US-5126337-A Wide-spectrum bactericides HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1992-06-30 US disclosed
EP-0393538-A2 Thiazetoquinoline-3-Carboxylic acid derivative, method for preparation thereof, and a pharmaceutical composition comprising the same HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1990-10-24 EP disclosed